pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
Pimavanserin
Approved · small molecule · Parkinson Disease Psychosis
Pimavanserin for Parkinson Disease Psychosis is a Approved program (small_molecule) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).
Internal code ACP-103-063
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acadia Pharmaceuticals B.V.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Parkinson Disease Psychosis
- Status
- completed
- Trials
- 1